Biomarkers for treatment selection in colon cancer

There have been tremendous advancements in the multidisciplinary management of GI cancers in the past decade, with a growing number of new and improved targeted agents and efficacious combination regimens yielding substantial clinical benefits in both early and late stages of the diseases. Moreover, breakthroughs in molecular profiling, cancer immunology, early stage detection, and novel diagnostic techniques have led to accelerated strides in GI cancer research and management.

As the field of GI malignancies is continuously evolving, community oncologists must strive to keep abreast of the latest developments and resolve new issues in optimizing the management of esophageal, gastric, hepatocellular, pancreatic, and colorectal cancers. To this end, this webcast highlights the clinically significant information presented during the 2016 Great Debates and Updates in GI Malignancies in New York, New York from April 1-2, 2016.

In this presentation, Dr. Christopher H. Lieu discusses the use of biomarkers for colon cancer treatment selection.

Earn accreditation for this activity at the following location:
http://elc.imedex.com/ELC/Acti....vity-Search.aspx?sea

© 2016 Imedex, LLC.